Find out more about the science behind our company.

To design nanobody-based drugs, scientists need databases that collate the increasing volume of biological sequence data in the public domain. To address this problem, we developed Integrated Nanobody Database for Immunoinformatics (INDI) - a novel nanobody database that collates nanobody information from all the major data repositories in the public domain.

AbDiver is an online platform that helps scientists to navigate the vast NGS data sets on antibody mutations. Allowing to draw parallels between natural and therapeutic antibodies, the solution supports and accelerates the decision-making process in the rational design of therapeutics at the lead optimization stage for a faster therapeutic pipeline.

We’re excited to share that the Management Board of NaturalAntibody was awarded a top 10 position in the 11th edition of the 50 Most Creative People in Business Ranking.

By accessing antibody data in patent documents via NaturalAntibody infrastructure, researchers can accelerate the antibody development process. They can quickly check whether the sequence they’re working on has already been developed by another company and use data stored in patents to study similar antibodies with their targets and engineering properties.

​​We have fantastic news to share today - Jakob Saga joined NaturalAntibody as Chief Commercial Officer! Mr. Saga has over 12 years of experience in the pharmaceutical industry, working as a Finance Manager and CFO in globally renowned companies. His business acumen and expert knowledge are going to support our team in realizing our mission of accelerating antibody-based drug discovery to deliver life-saving therapeutics faster.